'מערכת אימד'Abstract
Objective
To directly compare aripiprazole once-monthly 400 mg (AOM 400) and paliperidone palmitate once-monthly (PP) on the Heinrichs–Carpenter Quality-of-Life Scale (QLS), a validated health-related quality of life and functioning measure in schizophrenia.
Dieter Naber, Karina Hansen, Carlos Forray, Ross A. Baker, Christophe Sapin, Maud Beillat, Timothy Peters-Strickland, Anna-Greta Nylander, Peter Hertel, Henrik Steen Andersen, Anna Eramo, Jean-Yves Loze, Steven G. Potkin,
Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia,
Schizophrenia Research, Volume 168, Issues 1–2, 2015, Pages 498-504, ISSN 0920-9964, https://doi.org/10.1016/j.schres.2015.07.007.
(https://www.sciencedirect.com/science/article/pii/S0920996415003461)
Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia,
Schizophrenia Research, Volume 168, Issues 1–2, 2015, Pages 498-504, ISSN 0920-9964, https://doi.org/10.1016/j.schres.2015.07.007.
(https://www.sciencedirect.com/science/article/pii/S0920996415003461)